Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer
Abstract Objective The KEYNOTE‐590 trial showed that individuals with advanced esophageal cancer who received Pembrolizumab in combination with chemotherapy as a first‐line regimen achieved a significant extension of survival. However, this treatment option increases the financial burden on patients...
Main Authors: | Zhuo‐Miao Ye, Zhe Xu, Hao‐Lun Wang, Ying‐Yuan Wang, Ze‐Chang Chen, Qin Zhou, Xiang‐Ping Li, Ying‐Ying Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-03-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5350 |
Similar Items
-
Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
by: Jia Hu, et al.
Published: (2022-12-01) -
Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
by: Zhuo-Miao Ye, et al.
Published: (2022-11-01) -
Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer
by: Ying-tao Lin, et al.
Published: (2024-01-01) -
Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022-08-01) -
Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
by: Hongtao Duan, et al.
Published: (2022-06-01)